By coating tiny gel beads with lung-derived stem cells and then allowing them to self-assemble into the shapes of the air sacs found in human lungs, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have succeeded in creating three-dimensional lung “organoids.” The laboratory-grown lung-like tissue can be used to study diseases including idiopathic pulmonary fibrosis, which has traditionally been difficult to study using conventional methods.
“While we haven’t built a fully functional lung, we’ve been able to take lung cells and place them in the correct geometrical spacing and pattern to mimic a human lung,” said Dr. Brigitte Gomperts, an associate professor of pediatric hematology/oncology and the study’s lead author.
Idiopathic pulmonary fibrosis is a chronic lung disease characterized by scarring of the lungs. The scarring makes the lungs thick and stiff, which over time results in progressively worsening shortness of breath and lack of oxygen to the brain and vital organs. After diagnosis, most people with the disease live about three to five years. Though researchers do not know what causes idiopathic pulmonary fibrosis in all cases, for a small percentage of people it runs in their families. Additionally, cigarette smoking and exposure to certain types of dust can increase the risk of developing the disease.
To study the effect of genetic mutations or drugs on lung cells, researchers have previously relied on two-dimensional cultures of the cells. But when they take cells from people with idiopathic pulmonary fibrosis and grow them on these flat cultures, the cells appear healthy. “Scientists have really not been able to model lung scarring in a dish,” said Gomperts, who is a member of the UCLA Broad Stem Cell Research Center. The inability to model idiopathic pulmonary fibrosis in the laboratory makes it difficult to study the biology of the disease and design possible treatments.
Gomperts and her colleagues started with stem cells created using cells from adult lungs. They used those cells to coat sticky hydrogel beads, and then they partitioned these beads into small wells, each only 7 millimeters across. Inside each well, the lung cells grew around the beads, which linked them and formed an evenly distributed three-dimensional pattern. To show that these tiny organoids mimicked the structure of actual lungs, the researchers compared the lab-grown tissues with real sections of human lung.
“The technique is very simple,” said Dan Wilkinson, a graduate student in the department of materials science and engineering and the paper’s first author. “We can make thousands of reproducible pieces of tissue that resemble lung and contain patient-specific cells.”
Moreover, when Wilkinson and Gomperts added certain molecular factors to the 3-D cultures, the lungs developed scars similar to those seen in the lungs of people who have idiopathic pulmonary fibrosis, something that could not be accomplished using two-dimensional cultures of these cells.
Using the new lung organoids, researchers will be able to study the biological underpinnings of lung diseases including idiopathic pulmonary fibrosis, and also test possible treatments for the diseases. To study an individual’s disease, or what drugs might work best in their case, clinicians could collect cells from the person, turn them into stem cells, coax those stem cells to differentiate into lung cells, then use those cells in 3-D cultures. Because it’s so easy to create many tiny organoids at once, researchers could screen the effect of many drugs. “This is the basis for precision medicine and personalized treatments,” Gomperts said.
The Latest on: Precision medicine
via Google News
The Latest on: Precision medicine
- Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaborationon May 12, 2020 at 2:14 am
TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ -- Regeneron Genetics Center will sequence 450,000 informed and consented patients Sequencing data will be paired with de-identified health ...
- Regeneron and CCPM collaborate to advance human genetics, precision medicineon May 11, 2020 at 4:16 pm
Regeneron Pharmaceuticals, Inc. and the Colorado Center for Personalized Medicine at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to ...
- Analyzing the Role of Pharmacovigilance Analytics for German Precision Medicine Market | A Quantzig Success Storyon May 11, 2020 at 11:18 am
Considering the growing complexities around drug development and drug safety, pharmacovigilance departments within the precision medicine market must have in place a robust process to identify risks ...
- “Direct to Drug” screening as a precision medicine tool in multiple myelomaon May 11, 2020 at 8:54 am
Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug ...
- Regeneron & Colorado Center for Personalized Medicine announce human genetics research collaborationon May 11, 2020 at 6:33 am
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus today announced a large-scale research ...
- Caris Life Sciences to Present Data Spotlighting Clinical Impact of Precision Medicine in ASCO20 Virtual Scientific Programon May 11, 2020 at 3:30 am
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced ...
- Role of Pharmacovigilance in Precision Medicine Marketon May 8, 2020 at 6:13 am
Quantzig has announced the completion of its recent engagement- Pharmacovigilance: Improving Drug Development Amid The Covid-19 Crisis ...
- Precision public health may be the answer to COVID-19: Opinionon May 7, 2020 at 2:20 am
Instead of relying on a one-size-fits-all approach, we need to rapidly develop a precision public health approach to containing the virus. It should be centered on case finding (identifying people ...
- AI-enabled precision medicine may increase survival rate of patients with COVID-19-related sepsison May 6, 2020 at 10:28 pm
Data scientists from UK-headquartered AI precision medicine company, PrecisionLife, have used the Company’s proprietary AI enabled precision medicine platform to identify 59 repurposing drug ...
via Bing News